OncoCyte Corporation (LON:0KCC)
London flag London · Delayed Price · Currency is GBP · Price in USD
3.080
0.00 (0.00%)
At close: Apr 24, 2025

OncoCyte Company Description

OncoCyte Corporation, a precision diagnostics company in the United States and internationally.

It develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests.

The company is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.

It also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs.

It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests.

The company has a collaboration agreement with Bio-Rad Laboratories, Inc. to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents.

OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

OncoCyte Corporation
Country United States
Founded 2009
Industry Medical - Pharmaceuticals
Sector Healthcare
Employees 49
CEO Joshua Riggs

Contact Details

Address:
15 Cushing
Irvine, California 92618
United States
Phone 949 409 7600
Website oncocyte.com

Stock Details

Ticker Symbol 0KCC
Exchange London Stock Exchange
Fiscal Year January - December
Reporting Currency USD
ISIN Number US68235C2061
SIC Code 2836

Key Executives

Name Position
Dr. Michael D. West Ph.D. Scientific Advisor, Co-Chief Executive Officer of Biotime,Inc. and President of Biotime,Inc.
Joshua Riggs President, Chief Executive Officer and Director
James Liu Senior Director, Controller and Principal Accounting Officer
Dr. Ekkehard Schutz M.D., Ph.D. Chief Science Officer
Andrea Susan James Chief Financial Officer
Yuh-Min Chiang Ph.D. Chief Technology Officer
Peter Hong Vice President, General Counsel and Secretary
Sandra O'Donald Senior Vice President of Business Operations